TopoTarget A/S Release: Belinostat Gets European Orphan Drug Designation for the Treatment of Malignant Thymomas

Published: Jul 18, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

The EU regulation on orphan medicinal products is intended to encourage the development of drugs that may provide a significant benefit to patients suffering from rare (affecting fewer than five out of 10,000 people) and life-threatening or chronic debilitating conditions for which there is no effective therapies available. The orphan drug designation offers important incentives such as free protocol assistance (to optimize drug development) at the European Medicines Agency (EMA), fee reductions for various regulatory activities and, following drug approval, a grant of 10 years’ market exclusivity in the EU.

Help employers find you! Check out all the jobs and post your resume.

Back to news